High-Risk Non-Muscle-Invasive Bladder Cancer
AZNAstrazenecaCatalyst overview
Research summary
This catalyst tracks a Approved update for Imfinzi/Durvalumab + Bacillus Calmette-Guérin (MEDI4736) (PD-L1 Inhibitor) in High-Risk Non-Muscle-Invasive Bladder Cancer. The expected timing is based on the latest available company guidance and may change.
05/14/26:- POTOMAC Ph3 met disease-free survival endpoint; program under review in US, EU, and Japan. 05/22/26:- POTOMAC 5-year OS/PRO data June 1, 2026. 05/28/26:- FDA approved Imfinzi plus BCG for BCG-naïve high-risk NMIBC; POTOMAC 5-year overall survival and patient-reported outcomes data June 1, 2026.
Verification
Confirm timing and program details against the company announcement or filing.